



## **REGULATED INFORMATION**

### **ABLYNX RECEIVES TRANSPARENCY NOTIFICATION FROM OPPENHEIMER FUNDS, INC.**

**GHENT, Belgium, 15 September 2016** – Ablynx [*Euronext Brussels: ABLX; OTC: ABYLY*] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from Oppenheimer Funds, Inc.

Oppenheimer Funds, Inc. notified Ablynx that they have dropped below the 3% threshold on 12 September 2016 and now hold 1,734,184 Ablynx shares, representing 2.85% of the current 60,910,744 outstanding Ablynx shares.

Full versions of all transparency notifications are available on Ablynx website, under the section [Investors](#).

#### **About Ablynx**

[Ablynx](#) is a biopharmaceutical company engaged in the development of [Nanobodies®](#), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than [45 proprietary and partnered programmes](#) in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on [www.ablynx.com](http://www.ablynx.com).

#### **For more information, please contact:**

##### **Ablynx**

Dr Edwin Moses

CEO

t: +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e: [edwin.moses@ablynx.com](mailto:edwin.moses@ablynx.com)

Marieke Vermeersch

Director IR & Corporate Communications

t: +32 (0)9 262 00 82

m: +32 (0)479 49 06 03

e: [marieke.vermeersch@ablynx.com](mailto:marieke.vermeersch@ablynx.com)

[@AblynxABLX](#)

#### **Ablynx media/analyst relations:**

##### **FTI Consulting**

Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss

t: +44 20 3727 1000

e: [ablynx@fticonsulting.com](mailto:ablynx@fticonsulting.com)

#### **Disclaimer**

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those

expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.